Abstract
目的探讨抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型(EN-NK/T-NT)中的表达及其与PI3K/AKT通路活化的关系。方法以10例EN-NK/T-NT患者病理组织标本和PRDM1阳性细胞系YT细胞、PRDM1缺失细胞系NKL、NK92细胞为研究对象,采用免疫细胞化学和Western blot法检测PRDM1、p-AKT的表达,采用NanoString基因表达谱技术检测PI3K/AKT通路在正常鼻黏膜、PRDM1阴性和阳性EN-NK/T-NT组织中的激活情况,采用MTS法检测YT、NKL和NK92细胞增殖活性,采用流式细胞术检测细胞周期和细胞凋亡。结果①NanoString基因表达谱分析结果显示PRDM1阳性组PI3K/AKT信号通路IL-7、BRCA1、ITGA8、IL2RB、FASLG、CDK2、COL27A1、CSF3R、KITLG、IL-6的表达明显高于对照组,差异均有统计学意义(P值均<0.05)。②免疫细胞化学和Western blot法检测结果显示p-AKT在YT细胞系中高表达,而在NK92和NKL细胞中低表达或不表达。③Western blot法检测结果显示,PI3K/AKT通路抑制剂LY294002作用24 h后YT细胞PRDM1和PTEN的表达水平升高,且呈剂量依赖性。④LY294002(20 µmol/L)作用48 h后,与对照组比较,YT细胞增殖率较对照组明显降低(100.00%对58.18%,t=−12.770,P=0.006),G1期细胞比例明显增高(30.05%对76.93%,t=11.570,P<0.001),差异均有统计学意义;但NKL细胞与对照组比较细胞增殖和细胞周期的差异均无统计学意义(P值均>0.05)。结论EN-NK/T-NT中PI3K/AKT通路活化与PRDM1阳性表达相关,抑制PI3K/AKT通路有望成为PRDM1阳性EN-NK/T-NT的治疗手段。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.